Derivation of GMP raw materials for use in regenerative medicine: HESC-based therapies, progress toward clinical application

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 4, 2007, Pages 448-452

  Hewitt, Z A ^a   Amps, K J ^a   Moore, H D ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE MEDICINE; CLINICAL MEDICINE; DISEASE TRANSMISSION; DRUG INDUSTRY; EMBRYONIC STEM CELL; GOOD MANUFACTURING PRACTICE; HEALTH CARE POLICY; HEALTH CARE QUALITY; PRIORITY JOURNAL; QUALITY CONTROL; REGENERATIVE MEDICINE; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SAFETY; SOMATIC CELL THERAPY; STANDARDIZATION; STEM CELL TRANSPLANTATION; TOTAL QUALITY MANAGEMENT; TRADITIONAL MEDICINE;

CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SEPARATION; EMBRYO RESEARCH; EMBRYONIC STEM CELLS; GOVERNMENT REGULATION; GREAT BRITAIN; HUMAN EXPERIMENTATION; HUMANS; QUALITY CONTROL; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

EID: 34548698676     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100321     Document Type: Review

References (17)

1. Amit, M. et al. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev. Biol. 227, 271-278 (2000).
2. Amit, M., Shariki, C., Margulets, V. & Itskovitz-Eldor, J. Feeder layer-and serum-free culture of human embryonic stem cells. Biol. Reprod. 70, 837-845 (2004).
3. Andrews, P.W. et al. The international stem cell initiative: toward benchmarks for human embryonic stem cell research. Nat. Biotechnol. 23, 795-797 (2005).
4. Li, Y., Powell, S., Brunette, E., Lebkowski, J. & Mandalam, R. Expansion of human embryonic stem cells in defined serum-free medium devoid of animal-derived products. Biotechnol. Bioeng. 91, 688-698 (2005).
5. Beattie, G.M. et al. Activin A maintains pluripotency of human embryonic stem cells in the absence of feeder layers. Stem Cells 23, 489-495 (2005).
6. Heiskanen, A. et al. N-glycolylneuraminic acid xenoantigen contamination of human embryonic stem and mesenchymal stem cells is substantially reversible. Stem Cells 25, 197-202 (2007).
7. Heron, C. et al. Clinical experience using cultured epithelial autografts leads to an alternative methodology for transferring skin cells from the laboratory to the patient. Regen. Med. 1, 809-821 (2006).
8. Klimanskaya, I., Chung, Y., Meisner, L., Johnson, J., West, M. & Lanza, R. Human embryonic stem cells derived without feeder cells. Lancet 365, 1636-1641 (2005).
9. Ludwig, T. et al. Derivation of human embryonic stem cells in defined conditions. Nat. Biotechnol. 24, 185-187 (2006).
10. Martin, M.J., Muotri, A., Gage, F. & Varki, A. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat. Med. 11, 228-232 (2005).
11. MHRA. Rules and Guidance for Pharmaceutical Manufacturers and Distributors, 7th edn. (Pharmaceutical Press, London, 2007).
12. Moustafa, M. et al. A new autologous keratinocyte dressing treatment for non-healing diabetic neuropathic foot ulcers. Diabet. Med. 21, 786-789 (2004).
13. Rajala, K. et al. Testing of nine different xeno-free culture media for human embryonic stem cell cultures. Hum. Reprod. 22, 1231-1238 (2007).
14. Reubinoff, B.E., Pera, M.F., Fong, C.Y., Trounson, A. & Bongso, A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat. Biotechnol. 18, 399-404 (2000).
15. Stojkovic, P. et al. Human-serum matrix supports undifferentiated growth of human embryonic stem cells. Stem Cells 23, 895-902 (2005).
16. Thomson, J.A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 (1998).
17. Xu, C. et al. Feeder-free growth of undifferentiated human embryonic stem cells. Nat. Biotechnol. 19, 971-974 (2001).